Eyestem Research announced positive results from its phase 1 trial ( NCT06394232) evaluating its investigational drug product ...

Eyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy ...

Eyestem Research, a Bangalore-based cell therapy company, is pleased to announce significant vision improvement in Phase 1 trials of its investigational drug, Eyecyte-RPEtm, in patients with ...

A cell-based subretinal implant shows promise in the treatment of geographic atrophy, achieving the unprecedented milestone ...

Geographic atrophy presents as a well-defined, round or oval area of hypopigmentation, indicating retinal pigment epithelium (RPE) and choriocapillaris atrophy. Several imaging techniques are used ...

Average improvement of 14.9 letters in visual acuity reported in the first six patients over a four-six month follow-up. Signs of disease reversal observed in some patients. Dr Jogin Desai, Founder ...

A novel DIPN method enhances GA segmentation by integrating ConvLSTM, projection attention, adaptive pooling, and contrastive ...

Geographic atrophy (GA), the late stage of age-related ... At first, small areas of cells in the outer part of the retina die. Doctors refer to these areas of damage as “lesions.” ...

Hear the story of Yves Daniel whose journey with Geographic Atrophy (GA) reveals daily challenges and unwavering resilience. His hope for future treatments underscores the urgent need for increased ...

Bilco from Yarmouth Greyhound Rehoming faces daily battles due to a genetic disease called Progressive Retinal Atrophy (PRA).